Matthew Krebs, M.D., Ph.D., is a clinical senior lecturer in experimental cancer medicine at the University of Manchester and leads early phase clinical trials at The Christie NHS Foundation Trust, Manchester, U.K. and joined Zai Lab’s Scientific Advisory Board in 2024.
Dr. Krebs brings to our Board extensive expertise in early phase drug development for lung cancer and precision medicine. He has served as principal or chief investigator on more than 50 and co-investigator on more than 100 international early phase clinical trials across a broad range of novel therapeutics and cancer indications. His translational research focuses on the clinical application of circulating tumour DNA (ctDNA) to guide personalized treatment selection and to monitor both treatment response and resistance to novel therapeutic agents.
Dr. Krebs is currently chief investigator for two national precision medicine initiatives in the U.K. to enhance recruitment to precision medicine early phase trials. Notably, Dr. Krebs is clinical lead for cancer genomics in the northwest of England, chairs a national Molecular Tumour Board and serves on a range of National Health Service (NHS) England national genomics committees including co-lead for the national circulating biomarker network of excellence.
Dr. Krebs received his M.D. from the University of Leicester, completed his general medical training at the University Hospitals of Leicester and Manchester and earned his Ph.D. in circulating biomarkers and developmental therapeutics at the University of Manchester.
